Stock Scorer

Ensysce Biosciences, Inc. (ENSC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 1.5M 3M 4.5M Q3 '21: 1.2M Q4 '21: 1.6M Q1 '22: 603.1K Q2 '22: 207.5K Q3 '22: 279.4K Q4 '22: 1.4M Q1 '23: 789.6K Q2 '23: 490.5K Q3 '23: 435.4K Q4 '23: 515K Q1 '24: 305.7K Q2 '24: 181.8K Q3 '24: 3.4M Q4 '24: 1.3M Q1 '25: 1.3M Q2 '25: 1.4M Q3 '25: 493.1K Q4 '25: 1.9M Q1 '26: 961K Q2 '26: 1.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -16.9M Q4 '21: -2M Q1 '22: -4.8M Q2 '22: -7.1M Q3 '22: -6.2M Q4 '22: -6.2M Q1 '23: -2.6M Q2 '23: -2.3M Q3 '23: -2.7M Q4 '23: -3.2M Q1 '24: -1.8M Q2 '24: -2M Q3 '24: 644.7K Q4 '24: -3.6M Q1 '25: -2M Q2 '25: -1.8M Q3 '25: -3.7M Q4 '25: -2.8M Q1 '26: -3.6M Q2 '26: -2.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -17.2M Q4 '21: -10M Q1 '22: -950.9K Q2 '22: -7.9M Q3 '22: -9.9M Q4 '22: -5.5M Q1 '23: -2.2M Q2 '23: -2.2M Q3 '23: -2.7M Q4 '23: -3.5M Q1 '24: -3.1M Q2 '24: -2M Q3 '24: 661.8K Q4 '24: -3.6M Q1 '25: -1.9M Q2 '25: -1.7M Q3 '25: -3.7M Q4 '25: -2.8M Q1 '26: -3.6M Q2 '26: -2.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -3.8M Q4 '21: -3.8M Q1 '22: -3.4M Q2 '22: -4.4M Q3 '22: -6.7M Q4 '22: -3.3M Q1 '23: -3.6M Q2 '23: -3.1M Q3 '23: -2.3M Q4 '23: -1.8M Q1 '24: -3.4M Q2 '24: -2.3M Q3 '24: -1M Q4 '24: -764.1K Q1 '25: -1.7M Q2 '25: -2.7M Q3 '25: -1.9M Q4 '25: -1.5M Q1 '26: -3.5M Q2 '26: -2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q4 '25: -1.5M Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 10M 20M 30M Q3 '20: 16.8M Q1 '21: 15.8M Q2 '21: 16.1M Q3 '21: 24.3M Q1 '22: 27.3M Q2 '22: 141.6K Q3 '22: 160.7K Q1 '23: 1.1M Q2 '23: 2.3M Q3 '23: 3.1M Q1 '24: 379.6K Q2 '24: 587.8K Q3 '24: 659.4K Q1 '25: 1.4M Q2 '25: 2.2M Q3 '25: 2.9M Q1 '26: 6.8M Q2 '26: 13M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-150.00 -100.00 -50.00 0.00 50.00 100.00 150.00 Q3 '20: -0.17 Q4 '20: 0.00 Q1 '21: -0.55 Q2 '21: -0.57 Q3 '21: -1.37 Q4 '21: -1.50 Q1 '23: -118.67 Q2 '23: -63.16 Q3 '23: -2.45 Q4 '23: -71.01 Q1 '24: -77.14 Q2 '24: -79.51 Q3 '24: -77.64 Q4 '24: -13.49 Q1 '25: -6.67 Q2 '25: -4.11 Q3 '25: -6.40 Q4 '25: -4.03 Q1 '26: -3.16 Q2 '26: -2.57 Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ENSC: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.